Search

Displaying results 3731 - 3740 of 10000 in total
  1. Drug

    Gestrinone

    go.drugbank.com/drugs/DB11619
    Approved

    However, from 1982 this drug attracted increased interest due to significant therapeutic effects in the treatment endometriosis. … Gestrinone was developed in the early 1970s and was tested clinically as a weekly oral contraceptive in Europe and North America.

  2. Drug

    Infigratinib

    go.drugbank.com/drugs/DB11886
    ApprovedInvestigationalWithdrawn

    [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.

  3. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    The impact of diabetic foot ulcers (DFU) on individuals and society is devastating. Failure to observe proper wound care in this condition often results in amputation. … Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997.

  4. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  5. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

    Mixtures: Regulex D CapInternational brands: Scatron D
  6. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.

  7. Drug

    Xenon Xe-129

    go.drugbank.com/drugs/DB17386
    ApprovedInvestigational

    [Helium-3] (He-3) is the one most commonly used due to its strong signal and favorable safety profile, but its use in other applications has affected its availability. … Lung MRIs are challenging due to the low proton density of this tissue, as well as the presence of artifacts due to respiration and cardiovascular pulsation movement and air–tissue interfaces.

    Synonyms: Xenon, isotope of mass 129m(8.88 d)
  8. Drug

    Zansecimab

    go.drugbank.com/drugs/DB16389
    Investigational

    Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).

  9. Drug

    Lepirudin

    go.drugbank.com/drugs/DB00001
    ApprovedWithdrawn

    at position 1 (N-terminal end). … [A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4.

  10. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular … [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.